Aadi intends to use the net proceeds from the private placement to fund certain upfront payments under its license agreement with WuXi Biologics (Shanghai FX) Co., Ltd. and for working capital and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback